These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 23644243)

  • 1. [Dyslipidemia - when are lipid lowering medications useful in clinical practice?].
    Blum MR; Stanga Z; Rodondi N
    Praxis (Bern 1994); 2013 May; 102(10):585-9. PubMed ID: 23644243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnosis and treatment of severe hyperlipidemia].
    Tonstad S; Leren TP; Ose L
    Tidsskr Nor Laegeforen; 1997 Nov; 117(29):4241-4. PubMed ID: 9441469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of familial dyslipidemias in 5-year-old children using the lipid phenotypes of parents. The STRIP project.
    Lapinleimu J; Nuotio IO; Lapinleimu H; Simell OG; Rask-Nissila L; Viikari JS
    Atherosclerosis; 2002 Feb; 160(2):417-23. PubMed ID: 11849666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.
    Haralambos K; Whatley SD; Edwards R; Gingell R; Townsend D; Ashfield-Watt P; Lansberg P; Datta DB; McDowell IF
    Atherosclerosis; 2015 May; 240(1):190-6. PubMed ID: 25797312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biochemical diagnosis of hereditary hyperlipoproteinemias].
    Tvorogova MG; Rozhkova TA; Alidzhanova KhG; Semenova OA; Sobolev AV; Kukharchuk VV; Titov VN
    Ter Arkh; 1998; 70(4):9-15. PubMed ID: 9612894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [LDL-cholesterol control in patients with genetic dyslipidemia followed up by Lipid and Vascular Risk Units of the Spanish Society of Arteriosclerosis].
    Lahoz C; Mostaza JM; Pintó X; de la Cruz JJ; Banegas JR; Pedro-Botet J;
    Clin Investig Arterioscler; 2015; 27(1):1-8. PubMed ID: 24882148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing.
    McCrindle BW; Urbina EM; Dennison BA; Jacobson MS; Steinberger J; Rocchini AP; Hayman LL; Daniels SR; ; ;
    Circulation; 2007 Apr; 115(14):1948-67. PubMed ID: 17377073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
    Ceska R; Sobra J; Kvasnicka J; Procházková R; Kvasilová M; Haas T
    Cas Lek Cesk; 1996 Jul; 135(13):413-6. PubMed ID: 8925538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Practice Recommendations for Pediatric Dyslipidemia.
    Elkins C; Fruh S; Jones L; Bydalek K
    J Pediatr Health Care; 2019; 33(4):494-504. PubMed ID: 31227123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of bezamidine on plasma cholesterol and triglyceride levels in patients with familial hyperlipoproteinemia].
    Kukharchuk VV; Koshechkin VA; Konovalov GA; Rozhkova TA; Solov'eva EIu
    Kardiologiia; 1990 Dec; 30(12):16-8. PubMed ID: 2097388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harder-to-Treat Patients: Recognizing Them and Adapting Treatment Strategies.
    Miedema MD; Virani SS
    Am J Cardiol; 2016 Sep; 118(6 Suppl):13A-8A. PubMed ID: 27620355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and expression of familial combined hyperlipidemia in childhood.
    Cortner JA; Coates PM; Gallagher PR
    J Pediatr; 1990 Apr; 116(4):514-9. PubMed ID: 2319396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-lowering agents.
    Ewang-Emukowhate M; Wierzbicki AS
    J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):401-11. PubMed ID: 23811423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Essence of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan-2012 Version and Treatment Guide for Dyslipidemia 2013--Current Strategy for the Lipid Assessment].
    Arai H
    Rinsho Byori; 2014 Sep; 62(9):878-83. PubMed ID: 27526533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Update of lipid lowering therapy].
    Riesen WF; Mordasini RC
    Praxis (Bern 1994); 2008 Nov; 97(22):1179-84. PubMed ID: 18979436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Familial disorders of lipid metabolism in childhood].
    Herrmann W; Biermann J
    Z Arztl Fortbild (Jena); 1986; 80(17):725-8. PubMed ID: 3811401
    [No Abstract]   [Full Text] [Related]  

  • 18. [New guidelines for screening and management of familial dyslipidemia].
    Brun N; Aubert CE; Nanchen D; Rodondi N
    Rev Med Suisse; 2016 Mar; 12(508):435-9. PubMed ID: 27089599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 2: Hypercholesterolemia.
    Choluj B; Votruba T
    Acta Univ Carol Med (Praha); 1991; 37(3-4):106-15. PubMed ID: 1845465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel pharmacotherapies of familial hyperlipidemia.
    Drakopoulou M; Toutouzas K; Stefanadis C
    Pharmacol Ther; 2013 Sep; 139(3):301-12. PubMed ID: 23639874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.